Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Clinical Trial to Study the Effects of GRC 17536 in Patients With Painful Diabetic Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients)

This study has been withdrawn prior to enrollment.
(Due to new scientific evidence assessment, the study design was revised before the study started recruitment)
Glenmark Pharmaceuticals S.A.
Information provided by (Responsible Party):
Glenmark Pharmaceuticals Ltd. India Identifier:
First received: March 15, 2012
Last updated: November 9, 2012
Last verified: November 2012

March 15, 2012
November 9, 2012
Not Provided
Not Provided
Mean 24-hour average pain intensity (API) score [ Time Frame: 4 weeks ]
Same as current
Complete list of historical versions of study NCT01556152 on Archive Site
  • Mean night-time API Score [ Time Frame: 4 weeks ]
  • Patient Global Impression of Change [ Time Frame: 4 weeks ]
  • Clinician Global Impression of Change [ Time Frame: 4 weeks ]
  • Adverse events (AE) [ Time Frame: 4 weeks ]
  • Pharmacokinetics: Cmax, Tmax, AUC 0-tau, AUC0-24 [ Time Frame: 4 weeks ]
Same as current
Not Provided
Not Provided
A Clinical Trial to Study the Effects of GRC 17536 in Patients With Painful Diabetic Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients)
A Phase II, 4 Week Randomized, Double-Blind, Parallel Group, Placebo Controlled Proof of Concept Study to Evaluate Efficacy, Safety and Tolerability of GRC 17536 in Patients With Painful Diabetic Neuropathy

Diabetic peripheral neuropathy (DPN) represents a diffuse symmetric and length-dependent injury to peripheral nerves that has major implications on quality of life (QOL), morbidity, and costs from a public health perspective. Painful diabetic neuropathy affects 16% of patients with diabetes. Pharmacological agents used in the management of painful DPN mainly include tricyclic antidepressants, selective serotonin and norepinephrine reuptake inhibitors, opioids, and anti epileptic drugs. However, only two drugs (duloxetine and pregabalin) have been formally approved by the EMEA and the US FDA for the treatment of painful DPN. Generally, the available treatment options do not give total relief, are not effective in all patients, and only about one-third of patients may achieve more than 50% pain relief. Hence newer therapies are required for the treatment of DPN.

This is randomized, double-blind, placebo-controlled, parallel group study. The study will include patients with type 1 or type 2 diabetes mellitus with history of pain attributed to DPN for least 6 months and no greater than 5 years.

Patients will be recruited after providing written informed consent.

Not Provided
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Painful Diabetic Neuropathy
  • Drug: GRC 17536 (Medium Dose)
    1 BD for 28 days
  • Drug: GRC 17536 (Low Dose)
    1 BD for 28 Days
  • Drug: Placebo
    Matching Placebo for 28 Days
  • Active Comparator: Treatment Arm 1
    Intervention: Drug: GRC 17536 (Medium Dose)
  • Active Comparator: Traetment Arm 2
    Intervention: Drug: GRC 17536 (Low Dose)
  • Placebo Comparator: Treatment Arm 3
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided

Inclusion Criteria:

  1. Patients willing to provide voluntary written informed consent
  2. Male and female (women of non child-bearing potential) patients ≥18 yrs and ≤ 75 yrs
  3. Patients with diabetes mellitus with painful peripheral neuropathy for at least 6 months
  4. A baseline 24-hour average daily pain intensity score ≥5
  5. Women must be of non child-bearing potential, defined as post menopausal or surgically sterile.

Exclusion Criteria:

  1. Other chronic pain conditions not associated with DPN, that may confound the assessment of neuropathic pain
  2. Other causes of neuropathy or lower extremity pain
  3. Complex regional pain syndrome or trigeminal neuralgia
  4. Lower extremity amputations other than toes
  5. Participation in another study with an investigational compound within the previous 90 days prior to study medication administration, or concurrent participation in another clinical study
  6. Major depression.
  7. Presence or history of cancer within the past 5 years with the exception of adequately treated localized basal cell skin cancer or in situ uterine cervical cancer.
  8. Patients with clinically significant or uncontrolled hepatic, gastrointestinal, cardiovascular, respiratory, neurological (other than neuropathy), psychiatric, hematological, renal, or dermatological disease, or any other medical condition that according to Investigator's medical judgment: Could interfere with the accurate assessment of safety or efficacy, or, Could potentially affect a patient's safety or study outcome
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Germany,   United Kingdom
GRC 17536-201
2011-005879-16 ( EudraCT Number )
Not Provided
Not Provided
Not Provided
Glenmark Pharmaceuticals Ltd. India
Glenmark Pharmaceuticals Ltd. India
Glenmark Pharmaceuticals S.A.
Study Director: Dr. Kavita Muchandi, MD Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd. India
November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP